Impacto en la calidad de vida del tratamiento del cáncer de próstata organoconfinado / Impact of organ confined prostate cancer treatment on quality of life

INTRODUCCIÓN: El cáncer de próstata (CP) es el segundo cáncer más frecuente del mundo y en los varones. Se estima que la incidencia crezca a 1,7 millones de casos nuevos y 499.000 nuevas muertes en 2030. El tratamiento del cáncer de próstata organoconfinado (CPOC) puede afectar a un individuo tanto física como mentalmente, así como sus relaciones cercanas y su trabajo o vocación, lo cual condiciona la calidad de vida (CV) relacionada con la salud. OBJETIVO: Conocer el impacto en la CV atribuible al tratamiento del CPOC. MATERIALES Y MÉTODOS: Es un estudio observacional multicéntrico de carácter prospectivo de 406 pacientes con CPOC tratados desde enero del año 2015 hasta junio del 2018. La muestra se dividió en cuatro grupos de estudio (GA, GB, GC y GD), correspondientes a los distintos métodos de abordaje quirúrgico: prostatectomía radical (PR), radioterapia externa (RTE), braquiterapia (BT) y diferente a monoterapia con alguno de los otros, respectivamente. RESULTADOS: La edad en el GC fue inferior, la media del antígeno prostático específico (PSA, prostatic specific antigen) de todos los pacientes fue 8,13 ng/ml, el grupo de mayor media de PSA fue el GB con 10,43 ng/dL, la media del estadio tumoral (TNM,) fue 3,82, la CV postratamiento en GD fue inferior respecto a los demás grupos. CONCLUSIÓN: El tratamiento del CPOC afecta la CV La monoterapia curativa, concretamente la PR y la BT, afectan menos a la CV que la radioterapia externa u otras alternativas terapéuticas. La incontinencia urinaria y las fístulas secundarias al tratamiento del CPOC son las que producen más deterioro en la CV. El cuestionario SF 36 validado internacionalmente es una medida transversal de la CV, útil para comparar el impacto de los tratamientos del CPOC

INTRODUCTION: Prostate cancer (PCa) is the second most common male cancer in the world. Its incidence is estimated to grow to 1.7 million new cases and 499,000 new deaths by 2030. Treatment of OCPC can affect patients physically and mentally, as well as their close relationships and their job or career, which conditions health-related quality of life (QoL). OBJECTIVE: Evaluate the impact on QoL attributable to the treatment for Organ Confined Prostate Cancer (OCPC). MATERIALS AND METHODS: Prospective multicenter observational study of 406 patients with OCPC treated from January 2015 to June 2018. The sample was divided into four study groups, according to the type of treatment: radical prostatectomy (RP) (GA), external radiotherapy (ERT) (GB), brachytherapy (BT) (GC) and other treatments different from monotherapy with RP, ERT or BT (GD). RESULTS: The age in GC was lower, the mean Prostate Specific Antigen (PSA) of all patients was 8.13 ng/ml, the group with the highest mean PSA was GB with a mean of 10.43 ng/dL, the mean Tumor Stage (TNM) was 3.82, and GD had the lowest post treatment quality of life. CONCLUSION: OCPC treatment affects QoL. Curative monotherapies, specifically RP and BT, have less effect on QoL than external radiotherapy or other therapeutic alternatives. Urinary incontinence and fistulas secondary to OCPC have the highest impact on QOL impairment. The internationally validated SF 36 questionnaire is a useful cross-sectional measure of QOL to compare the impact of OCPC treatment modalities

Impact of organ confined prostate cancer treatment on quality of life. / Impacto en la calidad de vida del tratamiento del cáncer de próstata organoconfinado.

INTRODUCTION: Prostate cancer (PCa) is the second most common male cancer in the world. Its incidence is estimated to grow to 1.7 million new cases and 499,000 new deaths by 2030. Treatment of OCPC can affect patients physically and mentally, as well as their close relationships and their job or career, which conditions health-related quality of life (QoL). OBJECTIVE: Evaluate the impact on QoL attributable to the treatment for Organ Confined Prostate Cancer (OCPC). MATERIALS AND METHODS: Prospective multicenter observational study of 406 patients with OCPC treated from January 2015 to June 2018. The sample was divided into four study groups, according to the type of treatment: radical prostatectomy (RP) (GA), external radiotherapy (ERT) (GB), brachytherapy (BT) (GC) and other treatments different from monotherapy with RP, ERT or BT (GD). RESULTS: The age in GC was lower, the mean Prostate Specific Antigen (PSA) of all patients was 8.13 ng/ml, the group with the highest mean PSA was GB with a mean of 10.43 ng/dL, the mean Tumor Stage (TNM) was 3.82, and GD had the lowest post treatment quality of life. CONCLUSION: OCPC treatment affects QoL. Curative monotherapies, specifically RP and BT, have less effect on QoL than external radiotherapy or other therapeutic alternatives. Urinary incontinence and fistulas secondary to OCPC have the highest impact on QOL impairment. The internationally validated SF 36 questionnaire is a useful cross-sectional measure of QOL to compare the impact of OCPC treatment modalities.

Impacto del tiempo desde la biopsia a la prostatectomía radical en la infragradación del grado de Gleason y análisis de factores relacionados / The impact of time from biopsy to radical prostatectomy on Gleason score undergrading and other related factors

INTRODUCCIÓN: La infragradación del grado de Gleason de la biopsia (IGGB) puede impactar en el manejo y pronóstico de los pacientes con cáncer de próstata. Se analiza el posible impacto del tiempo y otros factores clínico-analíticos y la aparición de IGBB en nuestra serie. PACIENTES Y MÉTODO: Estudio multicéntrico ambispectivo de 1.955 pacientes con cáncer de próstata localizado intervenidos mediante prostatectomía radical entre 2005 y 2018. Se utiliza estadística descriptiva y pruebas de contraste de hipótesis con análisis uni- y multivariado para comunicar los RESULTADOS: RESULTADOS: Edad media 63,69 años (44-80), mediana de PSA 8,70 ng/ml (1,23-99). Se observa IGGB en el 34,7% de toda la muestra. En el 72,8% de los casos la IGGB fue en un único punto consecutivo del grado de Gleason: el paso de 3 + 3 a 3 + 4 fue el más frecuente (289 pacientes, 47,6%). La realización de prostatectomía radical antes o después de 90-180 días desde la biopsia no impactó en su infragradación en ninguno de los grupos. En los análisis uni- y multivariante, la presencia de tumor o tacto rectal patológico en ambos lóbulos, la carga tumoral ≥ 50% de los cilindros totales y una DPSA ≥ 0,20 mostraron capacidad discriminativa independiente para seleccionar pacientes que presentaron IGGB. CONCLUSIONES: El tiempo desde la biopsia hasta la prostatectomía radical no mostró impacto en IGGB. El número de cilindros afectados, la DPSA y presentar tumor bilateral fueron parámetros de fácil acceso que pueden ayudarnos a seleccionar pacientes con mayor probabilidad de presentar IGGB

INTRODUCTION: Gleason score biopsy undergrading (GSBU) can have an impact on the management and prognosis of patients with prostate cancer. We analyze the possible impact of time and other clinical and analytical factors in the appearance of GSBU in our series. PATIENTS AND METHOD: Ambispective, multicenter study of 1955 patients with localized prostate cancer undergoing radical prostatectomy between 2005 and 2018. Descriptive statistics and hypothesis testing are reported by univariate and multivariate analyses. RESULTS: Mean age 63.69 (44-80) years, median PSA 8.70 ng / ml (1.23-99). GSBU was observed in 34.7% of the entire cohort. In 72.8% of the cases, the GSBU occurred in one consecutive Gleason score, with the progression from 3 + 3 to 3 + 4 being the most frequent (289 patients, 47.6%). Performing radical prostatectomy 90-180 days before or after the biopsy does not have an impact on its undergrading in any of the groups. In the univariate and multivariate analysis, the presence of tumor or pathological rectal examination in both lobes, the tumor load ≥ 50% of cylinders and a DPSA ≥ 0.20, showed independent discriminative capacity to select patients who presented GSBU. CONCLUSIONS: The time from biopsy to radical prostatectomy did not show impact on GSBU. The number of affected cylinders, bilateral tumor and DPSA are easily accessible parameters that can help us select patients with greater probability of presenting GSBU

The impact of time from biopsy to radical prostatectomy on Gleason score undergrading and other related factors. / Impacto del tiempo desde la biopsia a la prostatectomía radical en la infragradación del grado de Gleason y análisis de factores relacionados.

INTRODUCTION: Gleason score biopsy undergrading (GSBU) can have an impact on the management and prognosis of patients with prostate cancer. We analyze the possible impact of time and other clinical and analytical factors in the appearance of GSBU in our series. PATIENTS AND METHOD: Ambispective, multicenter study of 1955 patients with localized prostate cancer undergoing radical prostatectomy between 2005 and 2018. Descriptive statistics and hypothesis testing are reported by univariate and multivariate analyses. RESULTS: Mean age 63.69 (44-80) years, median PSA 8.70 ng / ml (1.23-99). GSBU was observed in 34.7% of the entire cohort. In 72.8% of the cases, the GSBU occurred in one consecutive Gleason score, with the progression from 3 + 3 to 3 + 4 being the most frequent (289 patients, 47.6%). Performing radical prostatectomy 90-180 days before or after the biopsy does not have an impact on its undergrading in any of the groups. In the univariate and multivariate analysis, the presence of tumor or pathological rectal examination in both lobes, the tumor load ≥50% of cylinders and a DPSA ≥0.20, showed independent discriminative capacity to select patients who presented GSBU. CONCLUSIONS: The time from biopsy to radical prostatectomy did not show impact on GSBU. The number of affected cylinders, bilateral tumor and DPSA are easily accessible parameters that can help us select patients with greater probability of presenting GSBU.

Neoplasias hematológicas con implicación testicular / Hematologic neoplasms with testicular involvement

OBJETIVO: Presentamos dos casos de pacientes diagnosticados de tumor hematológico que presentan recidiva a nivel testicular, realizamos la revisión de la literatura en relación a lo infrecuente de dicha patología. MÉTODOS: Revisión retrospectiva de la historia clínica de dos pacientes diagnosticados de neoplasias hematológicas (Leucemia Mieloblástica Aguda y Mieloma múltiple) con aparición de recidiva a nivel testicular. Revisamos el manejo y resultado tras tratamiento mediante orquiectomía bilateral. RESULTADO: Caso 1: Paciente diagnosticado de Leucemia mieloblástica aguda tratada mediante trasplante alogénico. Dos años después el paciente refiere aumento del tamaño testicular. En estudios complementarios se sospecha recidiva a nivel testicular que tras orquiectomía se confirma. Actualmente se encuentra a la espera de tratamiento quimioterápico previo a nuevo trasplante alogénico. Caso 2: Paciente diagnosticado de Mieloma Múltiple que inicia tratamiento poliquimioterápico sin respuesta, se realiza trasplante alogénico. Tras cinco meses de remisión completa se evidencian signos de recidiva sistémica realizándose estudio para nuevo trasplante. Durante el mismo se objetiva posible recidiva a nivel testicular. Tras pruebas complementarias se realiza orquiectomía bilateral y se confirma el diagnóstico. Actualmente el paciente se encuentra en protocolo de trasplante alogénico tras tratamiento radio y quimioterápico. CONCLUSIONES: Actualmente el porcentaje de mortalidad, en los casos de recidiva a nivel testicular secundaria a neoplasia hematológica, ha disminuido pese al marcado aumento de su incidencia. Esto se debe, como en nuestros casos, a un diagnóstico precoz y al uso combinado de quimioterapia, radioterapia y cirugía. Esto se logra a través de un trabajo interdisciplinario entre urólogos, hematólogos, oncólogos y radioterapeutas

OBJECTIVE: We report two cases of patients with a previous diagnosis of hematologic tumor who present with testicular recurrence, and we carry out a review of the literature regarding the infrequency of this pathology. METHODS: We present a retrospective review of the medical records of two patients diagnosed with hematologic malignancies (acute myelogenous leukemia and multiple myeloma) with occurrence of relapse in the testicle. We reviewed the management and outcome after treatment with bilateral orchiectomy. RESULTS: Case 1: The patient was diagnosed with acute myeloid leukemia and treated with an allogeneic transplant. Two years later, the patient reported an increase in testicular size. The complementary studies lead us to suspect a testicular recurrence that was confirmed after orchiectomy. Currently, the patient awaits the start of a chemotherapy treatment prior to a new allogeneic transplant. Case 2: Patient with the diagnosis of multiple myeloma who started a polychemotherapy treatment without response and underwent allogeneic transplant. After five months with complete remission, there were signs of systemic recurrence, and a study for a new transplant was carried out. During the study, potential testicular recurrence was observed. After a batch of complementary tests, bilateral orchiectomy was performed and the diagnosis was confirmed. Currently, the patient is undergoing an allogeneic transplant protocol after radiotherapy and chemotherapy treatment. CONCLUSIONS: Currently the mortality rate in cases of relapse of hematologic malignancy in the testicle has declined despite the sharp rise in its incidence. This is because of, as in our case, early diagnosis and the combined use of chemotherapy, radiotherapy and surgery. This has been achieved through an interdisciplinary collaboration of urologists, hematologists, oncologists and radiotherapists

Fístula rectovaginal y enterocutánea espontáneas: potenciales complicaciones durante la terapia con fármacos antiangiogénicos en cáncer renal / Spontaneous enterocutaneous and rectovaginal fistula: potential complications during therapy with anti-angiogenic drugs in renal cancer

Se presentan dos casos de fístula, enterovaginal y enterocutánea asociadas a tratamiento con pazopanib, un inhibidor de la angiogénesis para el tratamiento de cáncer renal metastásico. El tiempo entre el inicio del fármaco y la aparición de la fístula fue de 6 y 16 meses, respectivamente; en ninguno de los casos hubo antecedentes de radioterapia o cirugía previa en la zona donde surgió la complicación. Según lo reportado en la literatura, alrededor de un 70% de pacientes se benefician de un tratamiento conservador. Las fístulas enterovaginales y enterocutáneas, suponen menos del 1% de las complicaciones publicadas por el uso de fármacos antiangiogénicos; a pesar de eso, es una complicación que deberíamos tener presente, pues se reporta una mortalidad cercana al 30%. A través de este artículo, queremos trasmitir nuestra experiencia en este tipo de complicación, ya por su baja incidencia, es indudable, que esta por vía de información, nos podemos apoyar los diferentes especialistas que tratan a estos pacientes; tomando las precauciones necesarias y decidiendo un manejo adecuado

We present two cases of enterovaginal and enterocutaneous fistulae associated to treatment with pazopanib, which is an angiogenesis inhibitor for the treatment of metastatic renal cancer. The times from drug administration and the first appearance of a fistula were 6 and 16 months, respectively. None of the cases had a history of surgery or radiotherapy in the area where the complication was observed. Enterovaginal and enterocutaneous fistula represent less than 1% of all published complications caused by the use of antiangiogenic drugs. However, they must be taken into account as the reported mortality rate is close to 30%. Given its low incidence, we believe that sharing this data is a great way to help specialists who have to treat these patients to take the necessary precautions and decide on an adequate approach

Tuberculosis de localización atípica en trasplantados renales / Atypical localisation of tuberculosis in kidney transplants

No disponible